Key result
Hispanic race was a strong independent predictor of subsequent LVEF decline after initial improvement on beta-blocker therapy in patients with non-ischemic cardiomyopathy.
Why the study?
Does race predict LVEF decline after initial improvement with beta blockers in patients with non-ischemic cardiomyopathy?
Cohort (n=238)
No
Does race predict LVEF decline after initial improvement with beta blockers in patients with non-ischemic cardiomyopathy?
A significant proportion of patients with non-ischemic cardiomyopathy experience LVEF decline after initial improvement on beta blockers, with Hispanic race being a strong predictor of this decline.
Answers are grounded in this paper and cite their sources.
Hispanic NICM patients may warrant closer LVEF surveillance after initial beta-blocker response; this association leaves open questions of causality and generalizability.
BACKGROUND: Although beta blockers (BBs) are established therapy in heart failure, some patients whose left ventricular ejection fraction (LVEF) initially increases on BB therapy experience a subsequent LVEF decline. This study aimed to evaluate the proportion of patients with non-ischemic cardiomyopathy (NICM) whose LVEF declines while on BB therapy and determine important predictors of LVEF decline. METHODS: A retrospective analysis of 238 patients receiving a BB (carvedilol, metoprolol succinate, or tartrate), with an ejection fraction of ≤40% and NICM, whose LVEF initially rose ≥5% after 1 year of BB therapy, was conducted. Post-response LVEF decline ≥5% to a final LVEF of ≤35% was evaluated within 4 years of BB initiation. RESULTS: In our study, we had 52 Caucasians (22%), 78 Hispanics (33%), and 108 African Americans (45%). Overall, 32 patients (13.44 %) had post-response LVEF decline. The nadir LVEF of patients with post-response LVEF decline was 25% (interquartile range 20-27). Compared with others, Hispanics had lower nadir LVEF (22%, p < 0.001). Important predictors of LVEF decline were Hispanic race (odds ratio (OR) 6.094, p < 0.001), New York Heart Association (NYHA) class (OR 2.287, p < 0.05), baseline LVEF (OR 1.075, p < 0.05), and age (OR 0.933, p < 0.001). CONCLUSION: A significant proportion (13.44%) of NICM patients with LVEF increase over 1 year of BB therapy experienced subsequent LVEF decline. Race, NYHA class, baseline LVEF, and age are important predictors of this decline.
No takes yet. Share an insight, caveat, or question.
Kelesidis et al. (2013) conducted a cohort in Non-ischemic cardiomyopathy (n=238). Hispanic race vs. Caucasian race was evaluated on Post-response LVEF decline (≥5% to a final LVEF of ≤35%) (OR 6.094, p=<0.001). Hispanic race was a strong independent predictor of subsequent LVEF decline after initial improvement on beta-blocker therapy in patients with non-ischemic cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: